Noraramtide | CAS 2580150-96-3 | Antibody Recruitment Molecule for Cancer Immunity Research

Description

Product Description

Noraramtide (BHV-1100) is a biologically active peptide designed as an antibody recruitment molecule. By binding specifically to CD38, Noraramtide recruits natural killer (NK) cells to tumor sites, enhancing their ability to recognize and eliminate cancer cells through antibody-dependent cellular cytotoxicity (ADCC). This targeted mechanism allows NK cells to attack tumor cells while minimizing mutual NK cell killing.

CD38 is a transmembrane glycoprotein widely expressed on hematologic malignancies such as multiple myeloma. Its selective targeting is critical for therapeutic research and preclinical models. Noraramtide’s high specificity and immunomodulatory properties make it a valuable tool in cancer immunotherapy research.

Preclinical studies have demonstrated that Noraramtide enhances NK cell cytotoxicity in vitro and in xenograft tumor models. The peptide’s design allows it to bridge NK cells with tumor cells, promoting localized immune responses and activating downstream cytotoxic pathways including perforin and granzyme release.

Research Applications:

• Autologous cancer immunity studies

• NK cell recruitment and activation research

• Hematologic malignancy models

• ADCC mechanism exploration

• Combination immunotherapy studies

Noraramtide is a fully synthetic peptide with high purity (≥99%) and is supplied as a lyophilized powder. It is stable under recommended storage conditions and is soluble in aqueous buffers and DMSO for in vitro and in vivo research applications.

Product Specifications

Mechanism of Action

Noraramtide functions by specifically binding to the CD38 receptor on tumor cells, creating a bridge to NK cells. This recruitment leads to:

• Enhanced ADCC: NK cells release cytotoxic granules containing perforin and granzyme, inducing apoptosis in tumor cells.

• Selective Targeting: CD38-positive tumor cells are preferentially targeted while sparing normal NK cells, minimizing self-cytotoxicity.

• Immune Activation: Noraramtide-mediated NK cell engagement promotes secretion of IFN-γ and TNF-α, enhancing antitumor immune signaling.

• Tumor Microenvironment Modulation: Recruited NK cells infiltrate the tumor microenvironment, disrupting immunosuppressive signals and promoting tumor cell clearance.

This multi-level mechanism makes Noraramtide an important tool for studying immunotherapeutic strategies, NK cell biology, and tumor-immune interactions.

Side Effects

As a research compound, human clinical data are not available. Experimental and preclinical studies indicate:

• Immune Activation: Potential cytokine release if NK cells are overstimulated in vitro.

• Cell Viability Effects: High concentrations may induce unintended cytotoxicity in non-target cell lines.

• Handling Precautions: Avoid inhalation, ingestion, or skin contact; use BSL-2 laboratory conditions.

All studies must comply with institutional safety and handling guidelines for peptide-based immunomodulatory agents.

Keywords

Noraramtide, BHV-1100, antibody recruitment peptide, NK cell recruiter, CD38 targeting peptide, ADCC research, cancer immunotherapy, autologous NK activation, CAS 2580150-96-3

Shipping Guarantee

All shipments are handled using validated cold-chain logistics to preserve peptide integrity. Each package is sealed in moisture-proof containers with secondary protective wrapping and continuous temperature monitoring. Products are shipped via express international couriers with full tracking and insurance coverage.

Trade Assurance

We ensure product authenticity, verified ≥99% purity, and compliance with analytical standards (HPLC, MS, and NMR). Each batch is supplied with a Certificate of Analysis (CoA). Our trade assurance policy guarantees replacement or refund for any deviation from listed specifications.

Payment Support

We provide flexible and secure global payment options to support international research transactions. Accepted payment methods include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are protected by industry-standard encryption to ensure confidentiality and fund security.